The Oswaldo Cruz Foundation (FIOCRUZ) Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials), is a multidisciplinary, integrated research consortium based in Rio de Janeiro, Brazil with two clinical research sites (CRS) located at the Institute de Pesquisa Clinica Evandro Chagas (IPEC CRS) and Hospital Geral de Nova Iguagu (HGNI CRS). Both sites offer routine clinical care for both "at-risk" and HIV-infected persons and cater to the needs of certain disenfranchised populations, which include individuals who may be racial minorities, women, poverty stricken, uneducated, and/or substance abusers. As a whole, the FioTrials unit has unique strengths to offer the ACTG and HPTN networks, as an established and integrated unit leadership who is partnered with FIOCRUZ, a supportive research-driven institution, a participant population that complements the scientific agendas of both networks, and researchers with significant experience in the development of HIV/AIDS prevention and treatment strategies. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
4UM1AI069476-06
Application #
8415479
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M2))
Program Officer
Castillo, Blanca E
Project Start
2008-01-15
Project End
2013-12-09
Budget Start
2013-01-01
Budget End
2013-12-09
Support Year
6
Fiscal Year
2013
Total Cost
$3,247,921
Indirect Cost
$22,748
Name
Fundacao Oswaldo Cruz
Department
Type
DUNS #
899294177
City
Rio de Janeiro
State
Country
Brazil
Zip Code
21040--360
Shivakoti, Rupak; Christian, Parul; Yang, Wei-Teng et al. (2016) Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr 35:183-9
Glidden, David V; Amico, K Rivet; Liu, Albert Y et al. (2016) Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis 62:1172-7
Shivakoti, Rupak; Yang, Wei-Teng; Berendes, Sima et al. (2016) Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings. J Infect Dis 213:1074-8
Nicol, Alcina F; Brunette, Laurie L; Nuovo, Gerard J et al. (2016) Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. J Acquir Immune Defic Syndr 73:27-33
Cesar, Carina; Koethe, John R; Giganti, Mark J et al. (2016) Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America. J Int AIDS Soc 19:20684
Mayer, Kenneth H; Grinsztejn, Beatriz; El-Sadr, Wafaa M (2016) Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action. J Acquir Immune Defic Syndr 72 Suppl 3:S207-9
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
Mave, Vidya; Erlandson, Kristine M; Gupte, Nikhil et al. (2016) Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis 214:65-72
Luetkemeyer, Anne F; Firnhaber, Cynthia; Kendall, Michelle A et al. (2016) Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis 62:1081-8
Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8

Showing the most recent 10 out of 62 publications